The Annual Blood-Brain Barrier Consortium Meeting

第十一届血脑屏障联盟年会定于2005年3月17-19日在俄勒冈州波特兰举行。会议的总体假设是，增加中枢神经系统恶性肿瘤和神经系统疾病的治疗可以提高生存率和生活质量，而不会增加系统或神经毒性。会议的目标是回顾脑屏障、脑肿瘤和神经系统疾病的基础科学、临床前和临床研究。每次会议都聚焦于研究进展可能影响大脑输送、成像或治疗的新领域。2005年会议的科学主题将是1)细胞和分子成像，2)纳米技术和纳米医学，以及3)化学保护。每次会议的一半时间用于开发新的临床方案。在2005年，临床会议将集中于1)临床方案的发展，以增加对原发性和转移性脑肿瘤的输送，2)化学保护，以及3)恶性脑肿瘤和中枢神经系统病变的磁共振成像。在之前的会议上，已经发表了五篇关于神经肿瘤临床试验中的剂量强度与神经毒性、原发性和转移性脑肿瘤的靶向给药以及预防毒性的策略的出版物。鼓励来自BBB联盟参与机构的主要研究者、临床工作人员和研究人员参加BBB年度会议。邀请杰出的科学家，以及临床医生和研究人员来自OHSU， NIH和其他大学的BBB和神经肿瘤学研究项目，特别强调转化研究。我们鼓励并招募少数民族、妇女和残疾临床医生和科学家参与。2005年BBB会议将继续为BBB联盟提供一个论坛，与研究人员会面，将临床前研究转化为临床，并制定多中心协议，以确定化疗敏感脑肿瘤的最佳治疗策略。

DESCRIPTION (provided by applicant): The Eleventh Annual Blood-Brain Barrier Consortium Meeting is scheduled for March 17-19, 2005, in Portland OR. The overall hypothesis of the meeting is that increased delivery of therapeutics in CNS malignancy and neurological diseases can improve survival and quality of life without increased systemic or neurological toxicity. The goals of the meeting are to review basic science, preclinical, and clinical research on the BBB, brain tumors, and neurological diseases. Every meeting spotlights new areas in which research advances may impact brain delivery, imaging, or therapy. The scientific session topics for the 2005 meeting will be 1) Cell and Molecular imaging, 2) Nanotechnology and nanomedicine, and 3) Chemoprotection. Half of each meeting is devoted to the development of new clinical protocols. In 2005, the clinical sessions will concentrate on 1) clinical protocol development to increase delivery to primary and metastatic brain tumors, 2) Chemoprotection, and 3) MR imaging of malignant brain tumors and CNS lesions. Five publications have been developed from previous meetings regarding dose intensity versus neurotoxicity in neuro-oncology clinical trials, targeted delivery in primary and metastatic brain tumors, and strategies for prevention of toxicity. Attendance at the annual BBB meeting is encouraged for principal investigators, clinical staff, and researchers from the participating institutions of the BBB Consortium. Distinguished scientists are invited to attend, as well as clinicians and researchers from OHSU, NIH, and other universities with research programs in the BBB and neuro-oncology, with a particular emphasis on translational research. We encourage and recruit the participation of minority, women and disabled clinicians and scientists. The 2005 BBB meeting will continue to provide a forum for the BBB Consortium to meet fellow researchers, translate preclinical research to the clinic, and develop multi-center protocols to determine optimal treatment strategies for chemo-sensitive brain tumors.